COVINGTON, Ky., April 18, 2011 /PRNewswire/ — Bexion
Pharmaceuticals was named the Biotech Innovation Award winner at
the Cincinnati USA Innovation Awards program sponsored by the
Cincinnati Business Courier, the Cincinnati USA Regional Chamber
and CincyTech. The Innovation Awards celebrate outstanding
innovation and the companies and people who have shown how new
ideas can be developed into fuel for the regional Tri-State
(Ohio/Kentucky/Indiana) economic engine.
“The Bexion team is honored to be the very first winner of the
Biotech Innovation Award,” stated Dr. Ray Takigiku, co-founder and
CEO of Bexion. “Cancer treatment and diagnosis is in dire
need of innovation. We believe, and the award judges appear
to agree, that our approach represents an entirely new, exciting
and potentially paradigm-shifting approach to the treatment of
cancer.”
Bexion is developing BXQ-350 nanovesicles as a potential
treatment for the form of brain cancer called glioblastoma.
BXQ-350 nanovesicles have an affinity for the membrane patches that
are common in many types of tumor cells including glioblastoma
cells. Bexion’s studies have shown effectiveness in the laboratory
in multiple animal tumor models, and across a remarkable range of
tumors in the test tube.
About Bexion Pharmaceuticals:Bexion Pharmaceuticals is
focused on the development and commercialization of innovative
cures for cancer. Initial products are based on a
patent-protected and proprietary platform technology licensed from
Cincinnati Children’s Hospital Medical Center. The technology
has demonstrated potential for development as therapeutics,
diagnostics and surgical imaging reagents, as well as carriers for
other pharmaceutical agents, such as oligonucleotides. For
more information, visit www.bexionpharma.com.For
media enquiries contact:
For investor enquiries contact:Margaret van GilseChuck
Scheper
‘/>”/>
